Dresser L, Wlodarski R, Rezania K, Soliven B (2021) Myasthenia gravis: epidemiology, pathophysiology and clinical manifestations. J Clin Med 10:2235. https://doi.org/10.3390/jcm10112235

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren J (2019) Myasthenia gravis. Nat Rev Dis Primers 5:30. https://doi.org/10.1038/s41572-019-0079-y

Article  PubMed  Google Scholar 

Howard JF Jr (2018) Myasthenia gravis: the role of complement at the neuromuscular junction. Ann N Y Acad Sci 1412:113–128. https://doi.org/10.1111/nyas.13522

Article  CAS  PubMed  Google Scholar 

Melzer N, Ruck T, Fuhr P, Gold R, Hohlfeld R, Marx A, Melms A, Tackenberg B, Schalke B, Schneider-Gold C, Zimprich F, Meuth SG, Wiendl H (2016) Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society. J Neurol 263:1473–1494. https://doi.org/10.1007/s00415-016-8045-z

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sanders DB, Wolfe GI, Benatar M, Evoli A, Gilhus NE, Illa I, Kuntz N, Massey JM, Melms A, Murai H, Nicolle M, Palace J, Richman DP, Verschuuren J, Narayanaswami P (2016) International consensus guidance for management of myasthenia gravis: executive summary. Neurology 87:419–425. https://doi.org/10.1212/wnl.0000000000002790

Article  PubMed  PubMed Central  Google Scholar 

Narayanaswami P, Sanders DB, Wolfe G, Benatar M, Cea G, Evoli A, Gilhus NE, Illa I, Kuntz NL, Massey J, Melms A, Murai H, Nicolle M, Palace J, Richman D, Verschuuren J (2021) International consensus guidance for management of myasthenia gravis: 2020 update. Neurology 96:114–122. https://doi.org/10.1212/WNL.0000000000011124

Article  PubMed  PubMed Central  Google Scholar 

Farmakidis C, Pasnoor M, Dimachkie MM, Barohn RJ (2018) Treatment of myasthenia gravis. Neurol Clin 36:311–337. https://doi.org/10.1016/j.ncl.2018.01.011

Article  PubMed  PubMed Central  Google Scholar 

Johnson S, Katyal N, Narula N, Govindarajan R (2021) Adverse side effects associated with corticosteroid therapy: a study in 39 patients with generalized myasthenia gravis. Med Sci Monit 27:e933296. https://doi.org/10.12659/MSM.933296

Article  PubMed  PubMed Central  Google Scholar 

Sharshar T, Porcher R, Demeret S, Tranchant C, Gueguen A, Eymard B, Nadaj-Pakleza A, Spinazzi M, Grimaldi L, Birnbaum S, Friedman D, Clair B (2021) Comparison of corticosteroid tapering regimens in myasthenia gravis: a randomized clinical trial. JAMA Neurol 78:426–433. https://doi.org/10.1001/jamaneurol.2020.5407

Article  PubMed  PubMed Central  Google Scholar 

Murai H (2015) Japanese clinical guidelines for myasthenia gravis: putting into practice. Clin Exp Neuroimmunol 6:21–31. https://doi.org/10.1111/cen3.12180

Article  Google Scholar 

Wiendl H, Meisel A (2022) Diagnostik und Therapie myasthener Syndrome, S2k-Leitlinie. Leitlinien für Diagnostik und Therapie in der Neurologie. https://www.awmf.org/service/awmf-aktuell/diagnostik-und-therapie-myasthener-syndrome

Jaretzki A, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, Sanders DB (2000) Myasthenia gravis: recommendations for clinical research standards. Task force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Ann Thorac Surg 70:327–334. https://doi.org/10.1016/s0003-4975(00)01595-2

Article  PubMed  Google Scholar 

Vissing J, Jacob S, Fujita KP, O’Brien F, Howard JF (2020) ‘Minimal symptom expression’ in patients with acetylcholine receptor antibody–positive refractory generalized myasthenia gravis treated with eculizumab. J Neurol 267:1991–2001. https://doi.org/10.1007/s00415-020-09770-y

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rollins SA, Sims PJ (1990) The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b–9. J Immunol 144:3478–3483

Article  CAS  PubMed  Google Scholar 

Thomas TC, Rollins SA, Rother RP, Giannoni MA, Hartman SL, Elliott EA, Nye SH, Matis LA, Squinto SP, Evans MJ (1996) Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Mol Immunol 33:1389–1401. https://doi.org/10.1016/s0161-5890(96)00078-8

Article  CAS  PubMed  Google Scholar 

Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L (2007) Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol 25:1256–1264. https://doi.org/10.1038/nbt1344

Article  CAS  PubMed  Google Scholar 

Howard JF Jr, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, Jacob S, Vissing J, Burns TM, Kissel JT, Muppidi S, Nowak RJ, O’Brien F, Wang JJ, Mantegazza R, REGAIN Study Group (2017) Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody–positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol 16:976–986. https://doi.org/10.1016/s1474-4422(17)30369-1

Article  CAS  PubMed  Google Scholar 

Muppidi S, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, Jacob S, Vissing J, Burns TM, Kissel JT, Nowak RJ, Andersen H, Casasnovas C, de Bleecker JL, Vu TH, Mantegazza R, O’Brien FL, Wang JJ, Fujita KP, Howard JF Jr, Regain Study Group (2019) Long-term safety and efficacy of eculizumab in generalized myasthenia gravis. Muscle Nerve 60:14–24. https://doi.org/10.1002/mus.26447

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alexion Pharmaceuticals Inc. (2024) Soliris prescribing information. https://alexion.com/Documents/Soliris_USPI.pdf. Accessed 24 Apr 2024

Muppidi S (2012) The myasthenia gravis-specific activities of daily living profile. Ann N Y Acad Sci 1274:114–119. https://doi.org/10.1111/j.1749-6632.2012.06817.x

Article  PubMed  Google Scholar 

Dodig D, Genge A, Selchen D, Freedman MS (2023) Complement inhibition in myasthenia gravis and neuromyelitis optica spectrum disorder. Can J Neurol Sci 50:165–173. https://doi.org/10.1017/cjn.2021.508

Article  PubMed  Google Scholar 

Kang SA, Sweeney M, Govindarajan R (2022) Academic and employment status in patients with generalized myasthenia gravis treated with eculizumab: a case series. J Clin Neuromuscul Dis 23:210–218. https://doi.org/10.1097/CND.0000000000000391

Article  PubMed  PubMed Central  Google Scholar 

Levine TD (2019) Safety of an abbreviated transition period when switching from intravenous immunoglobulin to eculizumab in patients with treatment-refractory myasthenia gravis: a case series. Am J Case Rep 20:965–970. https://doi.org/10.12659/AJCR.916424

Article  PubMed  PubMed Central  Google Scholar 

Oyama M, Okada K, Masuda M, Shimizu Y, Yokoyama K, Uzawa A, Kawaguchi N, Ikeguchi R, Hoshino Y, Hatano T, Ozawa Y, Nakahara J, Aizawa H, Kitagawa K, Hattori N, Kuwabara S, Murai H, Suzuki S (2020) Suitable indications of eculizumab for patients with refractory generalized myasthenia gravis. Ther Adv Neurol Disord 13:1756286420904207. https://doi.org/10.1177/1756286420904207

Article  CAS  PubMed  PubMed Central  Google Scholar 

Suh J, Clarke V, Amato AA, Guidon AC (2022) Safety and outcomes of eculizumab for acetylcholine receptor-positive generalized myasthenia gravis in clinical practice. Muscle Nerve 66:348–353. https://doi.org/10.1002/mus.27656

Article  CAS  PubMed  Google Scholar 

Murai H, Suzuki S, Fukamizu Y, Osawa T, Kikui H, Utsugisawa K (2022) Safety and effectiveness of eculizumab in Japanese patients with generalized myasthenia gravis: analysis of 1-year postmarketing surveillance. Clin Exp Neuroimmunol 13:280–289. https://doi.org/10.1111/cen3.12716

Article  CAS  Google Scholar 

Murai H, Suzuki S, Hasebe M, Fukamizu Y, Rodrigues E, Utsugisawa K (2021) Safety and effectiveness of eculizumab in Japanese patients with generalized myasthenia gravis: interim analysis of post-marketing surveillance. Ther Adv Neurol Disord 14:17562864211001996. https://doi.org/10.1177/17562864211001995

Article  CAS  PubMed  PubMed Central  Google Scholar 

Greene E, Cutter G, Muppidi S, Juel V, Rodrigues E, Korideck H, Howard JF Jr (2023) Myasthenia gravis activities of daily living (MG-ADL) response to eculizumab treatment in patients from the generalized myasthenia gravis registry (P1-5.020). Neurology 100:2071. https://doi.org/10.1212/wnl.0000000000202295

Article